Oppenheimer Initiates Coverage On Pacira BioSciences with Outperform Rating, Announces Price Target of $32

Oppenheimer analyst Les Sulewski has initiated coverage on Pacira BioSciences (NASDAQ: PCRX) with an Outperform rating. The firm has set a price target of $32 for the company's stock.